Drug–drug interactions and their implications on the pharmacokinetics of the drugs

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Pharmacokinetics and Toxicokinetic Considerations

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/b978-0-323-98367-9.00007-x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Software used in ADME computation

  2021cited by this paper
• Artificial intelligence in preventive and managed healthcare

  2021cited by this paper
• Innovation in bioanalytical strategies and in vitro drug-drug interaction study approaches in drug discovery.

  2021cited by this paper
• “Organ-on-a-chip”-based physiologically relevant pharmacokinetic models

  2021cited by this paper
• Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.

  2020cited by this paper
• Clinical trial design for medical devices “emerging pharmaceuticals”

  2020cited by this paper
• Artificial intelligence in the pharmaceutical sector: current scene and future prospect

  2020cited by this paper
• Artificial intelligence in drug discovery and development

  2020cited by this paper
• A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients.

  2020cited by this paper
• Performance Assessment of Software to Detect and Assist Prescribers with Antimicrobial Drug Interactions: Are all of them Created Equal?

  2020cited by this paper
• Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology.

  2019cited by this paper
• Predicting Drug-Drug Interactions Using Deep Neural Network

  2019cited by this paper
• Drug-Drug Interaction Predicting by Neural Network Using Integrated Similarity

  2019cited by this paper
• Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and N-Acetylprocainamide with Cimetidine, an Inhibitor of rOCT2 and rMATE1, in Rats

  2019cited by this paper
• Separating host and microbiome contributions to drug pharmacokinetics and toxicity

  2019cited by this paper
• Molecular modeling approaches for the discovery of adenosine A2B receptor antagonists: current status and future perspectives.

  2019cited by this paper
• PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol

  2018cited by this paper
• Computer-Aided Prediction of Pharmacokinetic (ADMET) Properties

  2018cited by this paper
• Impact of Pharmaceutical Product Quality on Clinical Efficacy

  2018cited by this paper
• Drug–Excipient Interaction and Incompatibilities

  2018cited by this paper
• Manifold regularized matrix factorization for drug-drug interaction prediction

  2018cited by this paper
• Warfarin and Flavonoids Do Not Share the Same Binding Region in Binding to the IIA Subdomain of Human Serum Albumin

  2017cited by this paper
• Food, gastrointestinal pH, and models of oral drug absorption

  2017cited by this paper
• In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods.

  2017cited by this paper
• Computational prediction of drug-drug interactions based on drugs functional similarities

  2017cited by this paper
• Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia

  2017cited by this paper
• PBPK modeling and simulation in drug research and development

  2016cited by this paper
• Lyophilized mucoadhesive-dendrimer enclosed matrix tablet for extended oral delivery of albendazole.

  2016cited by this paper
• Computerized techniques pave the way for drug-drug interaction prediction and interpretation

  2016cited by this paper
• Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA

  2016cited by this paper
• Application of Artificial Neural Networks in Modern Drug Discovery

  2016cited by this paper
• Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK

  2015cited by this paper
• Dealing with the complex drug-drug interactions: towards mechanistic models.

  2015cited by this paper
• Special Section on Drug Metabolism and the Microbiome—Perspective Gut Microbiota-Mediated Drug-Antibiotic Interactions

  2015cited by this paper
• PBPK models for the prediction of in vivo performance of oral dosage forms.

  2014cited by this paper
• In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.

  2014cited by this paper
• pH‐Dependent Drug–Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development

  2014cited by this paper
• Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.

  2014cited by this paper
• Understanding and preventing drug–drug and drug–gene interactions

  2014cited by this paper
• Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.

  2013cited by this paper
• Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects

  2013cited by this paper
• Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development

  2013cited by this paper
• Pharmacokinetic drug-drug interaction and their implication in clinical management

  2013cited by this paper
• Renal transporters in drug development.

  2013cited by this paper
• The effect of food on the absorption and pharmacokinetics of rivaroxaban.

  2013cited by this paper
• A diclofenac suppository–nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis

  2013cited by this paper
• Molecular displacement of warfarin from human serum albumin by flavonoid aglycones

  2013cited by this paper
• pH- and ion-sensitive polymers for drug delivery

  2013cited by this paper
• Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions

  2012cited by this paper
• QSAR study of necroptosis inhibitory activities (EC50) of [1,2,3] thiadiazole and thiophene derivatives using Bayesian regularized artificial neural network and calculated descriptors

  2012cited by this paper
• Physiologically-based pharmacokinetics in drug development and regulatory science.

  2011cited by this paper
• Potentially harmful drug-drug interactions in the elderly: a review.

  2011cited by this paper
• Clinically Significant Drug Interactions with Antacids

  2011cited by this paper
• Drug–Drug Interaction Studies

  2011cited by this paper
• Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions.

  2010cited by this paper
• Significance of protein binding in pharmacokinetics and pharmacodynamics.

  2010cited by this paper
• Drug-Drug Interaction Profiles of Proton Pump Inhibitors

  2010cited by this paper
• Predicting Drug–Drug Interactions: An FDA Perspective

  2009cited by this paper
• Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

  2009cited by this paper
• Degradation of DOPA by intestinal microorganisms in vitro.

  2009cited by this paper
• Drug-Drug Interactions in a Geriatric Outpatient Cohort

  2008cited by this paper
• Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats

  2008cited by this paper
• QSAR Analysis of Platelet-derived Growth Inhibitors Using GA-ANN and Shuffling Crossvalidation

  2008cited by this paper
• Pharmacology of proton pump inhibitors

  2008cited by this paper
• Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992 - 2002.

  2007cited by this paper
• A novel simple QSAR model for the prediction of anti-HIV activity using multiple linear regression analysis

  2006cited by this paper
• Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

  2006cited by this paper
• Ensembles of Bayesian‐regularized Genetic Neural Networks for Modeling of Acetylcholinesterase Inhibition by Huprines

  2006cited by this paper
• Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care.

  2005cited by this paper
• An in silico approach for screening flavonoids as P-glycoprotein inhibitors based on a Bayesian-regularized neural network

  2005cited by this paper
• DrugBank: a comprehensive resource for in silico drug discovery and exploration

  2005cited by this paper
• Predicting in vivo drug interactions from in vitro drug discovery data

  2005cited by this paper
• A molecular functional study on the interactions of drugs with plasma proteins.

  2005cited by this paper
• United States Food and Drug Administration Drug Approval Summary

  2004cited by this paper
• Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.

  2001cited by this paper
• Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research.

  2000cited by this paper
• Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

  2000cited by this paper
• Patient-Oriented Strategies for the Prevention of Drug Interactions

  2000cited by this paper
• Review article: drug interactions with agents used to treat acid‐related diseases

  1999cited by this paper
• Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil

  1999cited by this paper
• P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.

  1999cited by this paper
• Intraluminal pH of the human gastrointestinal tract.

  1999cited by this paper
• Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.

  1999cited by this paper
• Assessment of the Quality and Quantity of Drug‐Drug Interaction Studies in Recent NDA Submissions: Study Design and Data Analysis Issues

  1999cited by this paper
• Drug Interactions at the Renal Level

  1998cited by this paper
• Important Drug-Drug Interactions in the Elderly

  1998cited by this paper
• Effect of clarithromycin on renal excretion of digoxin: Interaction with P‐glycoprotein

  1998cited by this paper
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

  1997cited by this paper
• Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.

  1997cited by this paper
• Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine

  1997cited by this paper
• Itraconazole increases plasma concentrations of quinidine

  1997cited by this paper
• Physiological Parameter Values for Physiologically Based Pharmacokinetic Models

  1997cited by this paper
• Clinically Significant Drug Interactions with Cyclosporin An Update

  1996cited by this paper
• Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation

  1996cited by this paper
• Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein

  1996cited by this paper
• Inhibition of the intestinal digoxin absorption and exsorption by quinidine.

  1996cited by this paper
• Renal Drug Transport: A Review

  1996cited by this paper
• Comparison of the effects of over-the-counter famotidine and calcium carbonate antacid on postprandial gastric acid. A randomized controlled trial.

  1996cited by this paper
• Renal Disposition and Drug Interaction Screening of (–)-2′-deoxy-3′-thiacytidine (3TC) in the Isolated Perfused Rat Kidney

  1995cited by this paper
• Interaction of 3′‐Azido‐3′‐Deoxythymidine With the Organic Base Transporter in a Cultured Renal Epithelium

  1995cited by this paper

• Drug Utilization and Potential Drug-Drug Interactions of Proton Pump Inhibitors Among In-patients of Medicine Ward of a Tertiary Care Hospital, Pokhara, Nepal

  2026cites this paper
• The Effect of Cytochrome P450 and Organic Anion Transporter Polypeptide on Macrolides–Atorvastatin Drug Interaction

  2025cites this paper
• Outpatient prescription drug interactions at a city-affiliated healthcare center in Vietnam

  2024cites this paper
• Timing Matters: A Machine Learning Method for the Prioritization of Drug–Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure

  2024cites this paper
• Sex Differences in Cardiovascular Management: A Call for Better Acknowledgment—Part 1 Pharmacological Differences in Women and Men; How Relevant Are They?

  2024cites this paper
• An Optimized Hamiltonian Quantum Generative Network Based Drug-Drug Interactions Prediction Through Combining Local And Global Features

  2024cites this paper
• Enzyme-mediated drug-drug interactions: a review of in vivo and in vitro methodologies, regulatory guidance, and translation to the clinic

  2024cites this paper
• Probing the interaction behavior of Nano-Resveratrol with α-lactalbumin in the presence of β-lactoglobulin and β-casein: spectroscopy and molecular simulation studies

  2024cites this paper
• Current Pharmacotherapy and Multi-Target Approaches for Alzheimer’s Disease

  2022cites this paper
• Kratek pregled platform za ADME testiranje A narrative review of ADME testing platforms

  year unknowncites this paper